WO2024022580A1 - Novel esterase mutants and uses thereof as stereoselective catalyst - Google Patents
Novel esterase mutants and uses thereof as stereoselective catalyst Download PDFInfo
- Publication number
- WO2024022580A1 WO2024022580A1 PCT/EP2022/070973 EP2022070973W WO2024022580A1 WO 2024022580 A1 WO2024022580 A1 WO 2024022580A1 EP 2022070973 W EP2022070973 W EP 2022070973W WO 2024022580 A1 WO2024022580 A1 WO 2024022580A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- esterase
- mutant
- arthrobacter globiformis
- amino acid
- Prior art date
Links
- 108090000371 Esterases Proteins 0.000 title claims abstract description 92
- 239000003203 stereoselective catalyst Substances 0.000 title description 2
- XLOPRKKSAJMMEW-SFYZADRCSA-N (+)-trans-chrysanthemic acid Chemical compound CC(C)=C[C@@H]1[C@@H](C(O)=O)C1(C)C XLOPRKKSAJMMEW-SFYZADRCSA-N 0.000 claims abstract description 104
- 241000186074 Arthrobacter globiformis Species 0.000 claims abstract description 67
- 150000002148 esters Chemical class 0.000 claims abstract description 20
- 150000001942 cyclopropanes Chemical class 0.000 claims abstract description 14
- 230000007062 hydrolysis Effects 0.000 claims abstract description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 11
- 239000013604 expression vector Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 244000005700 microbiome Species 0.000 claims abstract description 5
- XLOPRKKSAJMMEW-UHFFFAOYSA-N chrysanthemic acid Chemical compound CC(C)=CC1C(C(O)=O)C1(C)C XLOPRKKSAJMMEW-UHFFFAOYSA-N 0.000 claims description 34
- 125000000539 amino acid group Chemical group 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 230000035772 mutation Effects 0.000 claims description 19
- 125000004494 ethyl ester group Chemical group 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 230000003301 hydrolyzing effect Effects 0.000 claims description 10
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108090000790 Enzymes Proteins 0.000 abstract description 36
- 102000004190 Enzymes Human genes 0.000 abstract description 36
- 239000013598 vector Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 230000002255 enzymatic effect Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- VIMXTGUGWLAOFZ-UHFFFAOYSA-N ethyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)C1C(C=C(C)C)C1(C)C VIMXTGUGWLAOFZ-UHFFFAOYSA-N 0.000 description 10
- 238000013537 high throughput screening Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000186063 Arthrobacter Species 0.000 description 8
- 239000002728 pyrethroid Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- VXSIXFKKSNGRRO-MXOVTSAMSA-N [(1s)-2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate;[(1s)-2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-3-[(e)-3-methoxy-2-methyl-3-oxoprop-1-enyl Chemical class CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1.CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VXSIXFKKSNGRRO-MXOVTSAMSA-N 0.000 description 6
- 239000002917 insecticide Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 6
- 229940070846 pyrethrins Drugs 0.000 description 6
- 238000002708 random mutagenesis Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000707 stereoselective effect Effects 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- DVDUMIQZEUTAGK-UHFFFAOYSA-N p-nitrophenyl butyrate Chemical compound CCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DVDUMIQZEUTAGK-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000250966 Tanacetum cinerariifolium Species 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 102000054767 gene variant Human genes 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- UIWNHGWOYRFCSF-KTERXBQFSA-N (1r,3r)-3-[(e)-3-methoxy-2-methyl-3-oxoprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylic acid Chemical compound COC(=O)C(\C)=C\[C@@H]1[C@@H](C(O)=O)C1(C)C UIWNHGWOYRFCSF-KTERXBQFSA-N 0.000 description 2
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 241000723353 Chrysanthemum Species 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108091007476 Microbial Esterases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- UIWNHGWOYRFCSF-UHFFFAOYSA-N Pyrethric acid Natural products COC(=O)C(C)=CC1C(C(O)=O)C1(C)C UIWNHGWOYRFCSF-UHFFFAOYSA-N 0.000 description 2
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 108010058834 acylcarnitine hydrolase Proteins 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229940015367 pyrethrum Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- XLOPRKKSAJMMEW-SFYZADRCSA-M (R,R)-chrysanthemate Chemical compound CC(C)=C[C@@H]1[C@@H](C([O-])=O)C1(C)C XLOPRKKSAJMMEW-SFYZADRCSA-M 0.000 description 1
- FMTFEIJHMMQUJI-NJAFHUGGSA-N 102130-98-3 Natural products CC=CCC1=C(C)[C@H](CC1=O)OC(=O)[C@@H]1[C@@H](C=C(C)C)C1(C)C FMTFEIJHMMQUJI-NJAFHUGGSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FMTFEIJHMMQUJI-UHFFFAOYSA-N Cinerin I Natural products C1C(=O)C(CC=CC)=C(C)C1OC(=O)C1C(C)(C)C1C=C(C)C FMTFEIJHMMQUJI-UHFFFAOYSA-N 0.000 description 1
- LTNDZDRYUXNFCU-NEWSRXKRSA-N Cinerin II Natural products CC=CCC1=C(C)[C@H](CC1=O)OC(=O)[C@@H]2[C@@H](C=C(C)OC(=O)C)C2(C)C LTNDZDRYUXNFCU-NEWSRXKRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NZKIRHFOLVYKFT-UHFFFAOYSA-N Jasmolin I Natural products C1C(=O)C(CC=CCC)=C(C)C1OC(=O)C1C(C)(C)C1C=C(C)C NZKIRHFOLVYKFT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VQXSOUPNOZTNAI-UHFFFAOYSA-N Pyrethrin I Natural products CC(=CC1CC1C(=O)OC2CC(=O)C(=C2C)CC=C/C=C)C VQXSOUPNOZTNAI-UHFFFAOYSA-N 0.000 description 1
- VMORCWYWLVLMDG-YZGWKJHDSA-N Pyrethrin-II Natural products CC(=O)OC(=C[C@@H]1[C@H](C(=O)O[C@H]2CC(=O)C(=C2C)CC=CC=C)C1(C)C)C VMORCWYWLVLMDG-YZGWKJHDSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- FMTFEIJHMMQUJI-DFKXKMKHSA-N cinerin I Chemical compound C1C(=O)C(C\C=C/C)=C(C)[C@H]1OC(=O)[C@H]1C(C)(C)[C@@H]1C=C(C)C FMTFEIJHMMQUJI-DFKXKMKHSA-N 0.000 description 1
- SHCRDCOTRILILT-WOBDGSLYSA-N cinerin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C)C(=O)C1 SHCRDCOTRILILT-WOBDGSLYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NZKIRHFOLVYKFT-VUMXUWRFSA-N jasmolin I Chemical compound C1C(=O)C(C\C=C/CC)=C(C)[C@H]1OC(=O)[C@H]1C(C)(C)[C@@H]1C=C(C)C NZKIRHFOLVYKFT-VUMXUWRFSA-N 0.000 description 1
- WKNSDDMJXANVMK-XIGJTORUSA-N jasmolin II Chemical compound C1C(=O)C(C\C=C/CC)=C(C)[C@H]1OC(=O)[C@H]1C(C)(C)[C@@H]1\C=C(/C)C(=O)OC WKNSDDMJXANVMK-XIGJTORUSA-N 0.000 description 1
- WKNSDDMJXANVMK-UHFFFAOYSA-N jasmolin II Natural products C1C(=O)C(CC=CCC)=C(C)C1OC(=O)C1C(C)(C)C1C=C(C)C(=O)OC WKNSDDMJXANVMK-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ROVGZAWFACYCSP-VUMXUWRFSA-N pyrethrin I Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-VUMXUWRFSA-N 0.000 description 1
- VJFUPGQZSXIULQ-XIGJTORUSA-N pyrethrin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-XIGJTORUSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
Definitions
- the present invention concerns the field of enzyme mutants, and in particular Arthrobacter globiformis esterase mutants suitable for asymmetrically hydrolyzing the cyclopropane derivatives, specifically chrysanthemate ester in any combination of the four stereoisomers in order to selectively obtain (1 R,3F?)-chrysanthemic acid or a salt thereof.
- the invention further describes an expression vector including the Arthrobacter globiformis esterase mutant and transformed host microorganisms harboring the vectors.
- the present invention further relates to the use of Arthrobacter globiformis esterase mutants to selectively obtain (1 R,3R)-chrysanthemic acid.
- the invention relates to the use of Arthrobacter globiformis esterase mutants for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters, preferably for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
- Tanacetum cinerariifolium or Dalmatian chrysanthemum is a species of white flowering plant in the aster family, which was formerly part of the genus Pyrethrum, but now placed in the genus Chrysanthemum.
- This plant is a natural source of "pyrethrum” insecticides, thereby giving it a great economic importance.
- the flowers are pulverized and the active components, called pyrethrins, contained in the seed cases, are extracted and sold in the form of an oleoresin which can be applied as a suspension in water or oil, or as a powder.
- Pyrethrins are a mixture of six structurally related insecticidal esters formed by a combination of two acids (chrysanthemic acid and pyrethric acid) and different alcohols.
- the esters of chrysanthemic acid are called pyrethrin I, cinerin I, and jasmolin I, respectively, and are together known as pyrethrins I
- the esters of pyrethric acid are called pyrethrin II, cinerin II, and jasmolin II, and together, the pyrethrins II Pyrethrins attack the nervous systems of all insects, inhibiting female mosquitoes from biting. When present in amounts less than those fatal to insects, they still appear to have an insect repellent effect.
- the Chrysanthemic acid is the peculiar intermediate that is related to a variety of natural and synthetic insecticides.
- the pyrethroids are derivatives of the chrysanthemic acid that can be found in different possible 4 stereoisomers i.e. (1 R,3R) or (1 R,3S) or (1 S,3R) or (1 S,3S).
- the (1 R,3R)- or (+)-trans-chrysanthemic acid (one of the four stereoisomers) is generally considered as the most interesting and effective of the four stereoisomers:
- the chrysanthemic acid can be obtained by hydrolysis of the appropriate chrysanthemic esters, in particular of ethyl chrysanthemate in racemic form.
- the ethyl chrysanthemate (or related esters) can be found in four isomers: (IS)-trans-ethyl chrysanthemate or (1S,3S)- ethyl chrysanthemate
- the stereoisomer mixture is the starting material for producing the chrysanthemic acid.
- a further object of the present invention is hence to selectively produce the (1 R,3R) chrysanthemic acid from the ethyl chrysanthemate racemate.
- the inventors surprisingly found a new esterase capable of selectively hydrolyzing an ester racemate of chrysanthemic acid to selectively produce (1 R,3R) chrysanthemic acid or salts thereof.
- the present invention hence concerns an Arthrobacter globiformis esterase mutant having a sequence comprising mutations of amino acid residue S at position 315, amino acid residue S at position 223 or amino acid residue F at position 298 of SEQ ID NO: 2.
- the present invention regards an expression vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- a third aspect of the present invention relates to a transformed host microorganism containing the expression vector, said vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- the present invention relates to the use of an Arthrobacter globiformis esterase mutant according to the invention, for the selective preparation of (1 F?,3F?)-chrysanthemic acid.
- the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing cyclopropane racemate derivatives having at least two chiral stereocenters.
- the invention relates to the use of the Arthrobacter globiformis esterase mutant for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
- the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing (C-i-Ce) alkyl chrysanthemate, preferably ethyl chrysanthemate.
- the invention relates to the use of the Arthrobacter globiformis esterase mutant for asymmetrically hydrolyzing (C-i-Ce) alkyl chrysanthemate, preferably ethyl chrysanthemate.
- the solution underlying the present invention is that of making available an innovative esterase with improved properties in obtaining the desired (1 R,3R) chrysanthemic acid for the production of pyrethroid insecticides.
- the problem of providing (1 F?,3F?)-chrysanthemic acid is solved by the present finding, particularly by the identification of mutants of the Arthrobacter globiformis esterase, having an improved enzyme kinetic, an improved enzyme stability and/or a reduced product inhibition when compared to the wild-type Arthrobacter globiformis esterase of SEQ ID NO:2, as identified in the attached claims.
- Figure 1 Comparison of the specific activity of raw extracts of cells expressing different esterase enzyme variants.
- the activity expressed as a percentage of the specific activity of the wild-type enzyme, was measured using 10% (v/v) racemate of ethyl ester of chrysanthemic acid as a substrate, measuring (1 F?,3F?) chrysanthemic acid formation by HPLC analysis.
- FIG. 2 Schematic representation of the functioning of the gene library generation kit: 1 . Megaprimer mutants synthesis: amplification of the gene encoding for the esterase S315M using a DNA polymerase prone to insertion mutations allows to obtain the gene variants which are purified. 2. Vector Libraries containing mutated genes generated in 1. are used as a megaprimer to amplify the target vector using a high-fidelity DNA Polymerase to obtain a library of vectors containing mutated gene versions of the S315M esterase enzyme. Figure 3: Representative graph of the variation of the specific activity as a function of the product concentration per an enzyme affected by product inhibition. Figure 4: Schematic representation of the selection scheme of the enzymatic variants obtained through random mutagenesis. Figure 5.
- the inventors deem that the Arthrobacter globiformis esterase mutants herein claimed allow to obtain a higher yield in the selective conversion of cyclopropane derivatives having at least two chiral centers, preferably the racemate of (C1-C6) alkyl ester of chrysanthemic acid to (1R,3R)-chrysanthemic acid or a salt thereof, more preferably the racemate of ethyl ester of chrysanthemic acid:
- a l bi i by influencing the following three aspects of the catalysis: i) improved enzyme stability at different temperatures and pH values: the enzyme has good operational stability under basic conditions, in the pH range between 9.0 and 11.00.
- the best conversion yields are also obtained in this range, preferably in the 10.0-10.5 range, with significant decreases below 8.5-9.0; ii) improved kinetic parameters; and iii) reduction of product inhibition, when compared to the wild-type Arthrobacter globiformis esterase with amino acid sequence described in SEQ ID NO:2.
- the mutants described have undergone improved changes in catalytic performance, achieving conversion yields of up to 88-95% compared to what is achievable with WT enzyme with amino acid sequence reported in SEQ ID NO:2, which does not exceed values of 40-49%, with pH-stat during the reaction.
- the mutations have increased the affinity towards the substrate, without altering the high stereospecificity of the enzyme and decreasing the product inhibition that remains evident in WT enzyme.
- the term: - “(1R,3R)-chrysanthemic acid” as used herein is intended to be synonymous to “(1R)- trans-chrysanthemic acid”, “(+)-trans-chrysanthemic acid” and “(1R,3R)- 2,2-Dimethyl- 3-(2-methyl-1-propenyl)cyclopropane-1-carboxylic acid” and having the CAS number 4638-92-0;
- - “(1R,3R)-chrysanthemic acid or its salts” means a salt of a metal selected from alkali metals and earth alkali metals such as potassium, sodium, calcium, magnesium, etc.;
- - “cyclopropane derivatives having at least two chiral centers” means cyclopropane compounds having at least two asymmetric carbon atoms so as to have at least two stereoisomers, preferably four stereoisomers;
- (C-i-Ce) alkyl esters of chrysanthemic acid means esters of a linear or branched alkyl chain of 1 to 6 carbon atoms of chrysanthemic acid, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, hexyl, etc.;
- Ethyl ester of chrysanthemic acid as used herein is intended to be synonymous to “ethyl 2,2-dimethyl-3-(2-methylprop-1 -enyl)cyclopropane-1 -carboxylate” and has the CAS number 97-41 -6.
- the ethyl ester of chrysanthemic acid can be provided in any ratio of trans/cis forms, for example from 60/40 to 100/0, preferably 65/35, 70/30, 80/20, 90/10, 92/8, 98/2.
- said amino acid residue S at position 315, said amino acid residue S at position 223 and said amino acid residue F at position 298 of SEQ ID NO: 2 are replaced with a non-polar amino acid residue chosen from the group consisting of M, F, L, W, A, I, P or V. It was surprisingly seen by the inventors that by replacing the amino acid residues present in position 315, 223 or 298 of SEQ ID NO:2 with a nonpolar amino acid, the characteristics of the esterase enzyme are improved and maintains the capability of asymmetrically hydrolyzing racemic esters of chrysanthemic acid.
- amino acid residues are indicated by their “one letter code”, wherein “M” corresponds to Met or methionine, “F” corresponds to Phe or phenylalanine, “S” corresponds to Ser or serine and so on, as a person with ordinary skill in the art would understand.
- said amino acid residue S at position 315, said amino acid residue S at position 223 and said amino acid residue F at position 298 of SEQ ID NO: 2 are replaced with a non-polar amino acid residue chosen from the group consisting of M, F, L or W.
- the Arthrobacter globiformis esterase mutant of the present invention has one of the following mutations S315M, S315F, S223M, S223L, S223F or F298W in the amino acid sequence of SEQ ID NO: 2.
- the Arthrobacter globiformis esterase mutant of the present invention has one further mutation (double mutant) or two further mutations (triple mutant), and is preferably chosen from the group consisting of:
- Preferred Arthrobacter globiformis esterase mutants have the following amino acid sequences: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20.
- Arthrobacter globiformis esterase mutant according to the present invention has the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 10 or SEQ ID NO: 12.
- the Arthrobacter globiformis esterase mutant according to the present invention has the amino acid sequence of SEQ ID NO: 12 and a corresponding nucleotide sequence such as SEQ ID NO:11 .
- This mutant is the S315M mutant of the Arthrobacter globiformis esterase.
- the invention also provides for the nucleotide sequences of the Arthrobacter globiformis esterase mutants, the mutants have the nucleotide sequences described in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- the present invention regards an expression vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- a third aspect of the present invention relates to a transformed host microorganism containing the expression vector, said vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- the present invention relates to the use of an Arthrobacter globiformis esterase mutant according to the invention, for the selective preparation of (1 F?,3F?)-chrysanthemic acid or a salt thereof.
- the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing cyclopropane racemate derivatives having at least two chiral stereocenters.
- the invention relates to the use of the Arthrobacter globiformis esterase mutant for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
- the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing (C-i-Ce) alkyl esters of chrysanthemic acid, preferably ethyl ester of chrysanthemic acid.
- the invention relates to the use of the Arthrobacter globiformis esterase mutant for asymmetrically hydrolyzing (C-i-Ce) alkyl ester of chrysanthemic acid, preferably ethyl ester of chrysanthemic acid.
- each Arthrobacter globiformis esterase sequence (wild type and mutant) has a corresponding SEQ ID NO: as follows, wherein for each mutant sequence the mutated nucleotide triplet or amino acid is indicated in bold and underlined:
- SEQ ID NO:1 corresponds to the nucleotide sequence of:
- Arthrobacter globiformis esterase Q44050 (Wild type) ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
- SEQ ID N0:2 corresponds to the amino acid sequence of:
- SEQ ID NO:3 corresponds to the nucleotide sequence of:
- SEQ ID N0:4 corresponds to the amino acid sequence of:
- SEQ ID NO:5 corresponds to the nucleotide sequence of:
- Arthrobacter alobiformis esterase mutant S223L (variant 15) ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
- SEQ ID N0:6 corresponds to the amino acid sequence of:
- SEQ ID N0:7 corresponds to the nucleotide sequence of:
- SEQ ID NO:8 corresponds to the amino acid sequence of:
- SEQ ID N0:9 corresponds to the nucleotide sequence of:
- SEQ ID NO:10 corresponds to the amino acid sequence of: Arthrobacter globiformis esterase mutant S315F (variant 18)
- SEQ ID N0:11 corresponds to the nucleotide sequence of:
- SEQ ID N0:12 corresponds to the amino acid sequence of:
- SEQ ID NO:13 corresponds to the nucleotide sequence of:
- SEQ ID N0:14 corresponds to the amino acid sequence of:
- SEQ ID NO:15 corresponds to the nucleotide sequence of:
- SEQ ID N0:16 corresponds to the amino acid sequence of:
- SEQ ID NO:17 corresponds to the nucleotide sequence of:
- SEQ ID N0:18 corresponds to the amino acid sequence of:
- SEQ ID NO:19 corresponds to the nucleotide sequence of:
- SEQ ID NO:20 corresponds to the amino acid sequence of:
- Example 1 Generation of a gene library of mutants encoding for the esterase enzyme
- the S315M mutant (also referred to as variant 19) was obtained.
- the S315M esterase mutant is characterized by a higher activity on the ester of chrysanthemic acid substrate and is used as a starting point (template) for a random mutagenesis cycle, as here described.
- the gene library was generated by random mutagenesis performed by using the commercial kit Genemorph II Random Mutagenesis Kit (Agilent cat. N° 200550), using the S315M esterase gene as a template ( Figure 2).
- the gene encoding the S315M esterase enzyme is used as a template in a PCR reaction conducted using the error-prone Mutazyme II DNA polymerase, and an amount of DNA and amplification cycles such as to determine a low mutation frequency, i.e. 0-4.5 mutations I Kbase.
- the gene variants thus obtained were loaded onto gel and the corresponding band was excised and then purified.
- the gene variants of the S315M enzyme, generated in phase 1 were used as megaprimer for the amplification of the target vector (generically a vector with a T7 promoter) by means of a high-fidelity DNA polymerase to avoid the introduction of mutations in the backbone of the vector.
- the mutated vector library was then purified and subsequently used for the transformation of E. coli cells.
- the “Esterase mutant” vector library was first fully amplified in E. coli DH5a. Following the amplification, plasmid DNA extraction was carried out as well as the transformation of overexpressing E. coli cells, suitable for gene expression.
- the cells thus transformed were plated on selective medium obtaining 10,832 colonies, after incubation over-night at 37°C. Of these, 1045 were randomly selected to then proceeded to the gene expression and subsequently to HTS.
- Each colony was inoculated into a deep well in 1 mL of ZYM5052 medium containing lactose, which is able to induce the expression of the genes encoding the variants of the esterase enzyme, inserted in the vector.
- the enzymes may be subject to inhibition by the substrate or by the product.
- Substrate inhibition In this case, there is a decrease in the initial specific activity as a function of substrate concentration.
- Previously collected cell pellets were lysed by resuspension in 200 pL of CellyticTM (enzymatic cocktail in detergent) and incubation at room temperature for 2 hours in agitation. The obtained lysate was clarified by centrifugation and the supernatant, ie. the total crude extract was used, after dilution, for screening.
- CellyticTM enzyme cocktail in detergent
- the enzymatic activity (U/mL) is therefore defined as: where E is the molar extinction coefficient of para-nitro-phenol.
- the total proteins in the crude extracts were quantified through the Bradford method, using BSA as the reference protein for the calibration curve.
- the HTS procedure allowed to obtain and select 25 enzyme variants.
- This value is calculated by making the ratio between the acid produced (g/L) and the maximum amount of acid obtainable (g/L).
- all 61 selected enzymes have an increase in residual activity compared to the starting enzyme of at least 25%.
- Figures 5 and 6 show the % increase in residual and specific activity (in the presence of (1 F?,3F?)-chrysanthemic acid) of each mutant with respect to the starting enzyme S315M.
- the growth of the 25 E. coli clones expressing the 25 enzymatic variants was performed in 250 mL flasks with 25 mL of self-inducing medium, instead of 1 mL deep wells.
- the 25 variants were also tested by providing the ethyl ester of chrysanthemic acid substrate.
- the selection of the three comparison mutants with the S315M reference was made from the previous 25 mutants by performing small-scale bioconversions with the chromogenic substrate but in the presence of chrysanthemic acid in the reaction mixture.
- the mutants with greater activity in the presence of the potential inhibitor (product inhibition) were then selected, thus demonstrating less influence from the acid.
- performance is naturally estimated with the substrate of interest.
- the reaction in pH stat is carried out in a final volume of 20 mL in the presence of the racemate ethyl ester of chrysanthemic acid as substrate at 10% (v I v).
- the reaction is carried out at 45°C for 20 hours during which the pH is maintained at a value of 9.5 by the addition of 1 M NaOH.
- the amount of (1 R, 3R) -chrysanthemic acid is evaluated by HPLC analysis.
- Figure 8 shows the HPLC chromatograms of the previous bioconversion obtained after 20 hours of reaction (T20) using 10% chrysanthemic acid ethyl ester (v/v). Specifically, the peaks at about 2 min will refer to (1 R,3R) chrysanthemic acid while those at about 4.7 min are related to all the chrysanthemic acid ethyl esters, not converted.
- the maximum yield which is theoretically obtainable was first calculated. From the analysis of the starting mixture of isomers of ethyl ester of chrysanthemic acid, the enantiomer ethyl ester of (1 R,3R) chrysanthemic acid is present at a concentration of 404.6 g/L. This mixture was used at 10% (v/v) therefore the reaction solution contained 40.46 g/L of ethyl ester of (1 R,3R)- chrysanthemic acid.
- the performance of the S223M variant was similar to S315M enzyme; in fact, it transformed a high percentage of substrate after an incubation of 20 hours, with a yield of about 89%, compared to the theoretical maximum obtainable yield.
- the S315M, S223M, S315F variants have proven to be the optimal ones to catalyze bioconversion of (1 F?,3F?)-ethyl ester of chrysanthemic acid to (1 R,3R)- chrysanthemic acid selectively from a mixture of the four possible stereoisomers.
- Example 5 Enzymatic hydrolysis of racemate ethyl ester of chrysanthemic acid 92/8
- Ethyl chrysanthemate 92/8 consisting of four stereoisomers was provided to produce (1 R,3R)- chrysanthemic acid by enzymatic hydrolysis reaction with the S315M mutant.
- the enzymatic hydrolysis reaction was conducted in batch; in addition to the 92/8 trans I cis ester mixture, glycine, enzyme and aqueous sodium hydroxide were loaded in a reactor, the function of which was to maintain the alkaline environment for the entire duration of the reaction.
- the enzyme degraded in an acidic environment by hydrochloric acid and denatured with trichloroacetic acid, was removed by filtration.
- the remaining solution containing the unconverted esters and the desired (1 R,3R) chrysanthemic acid was added with toluene to dissolve the esters and added with a solution (10% w/w) of aqueous sodium hydroxide to bring the chrysanthemic acid into water in the form of sodium salt. From the separation of these two phases, a toluene solution was obtained containing the unconverted esters which were fed to the subsequent workup stage; from the aqueous phase after acidification the product ( 1R,3R) chrysanthemic acid was recovered by extraction with toluene and subsequent evaporation of the solvent.
- the reaction was carried out on 400 kg of racemate ethyl ester of chrysanthemic acid 92/8 with 16.7 kg of glycine, 444 kg of enzyme dissolved in water, 413 kg of 10% aqueous sodium hydroxide in 3556 kg of water.
- the raw material was acidified with 1 16 kg of 37% hydrochloric acid and treated with 11 .6 kg of trichloroacetic acid to denature the enzyme and allow it to be filtered. From filtration approximately 17.4 kg of denatured enzyme were obtained and sent for disposal and a solution of toluene and water was introduced for washing the filter and extracting the esters using about 868 kg of it.
- the 5808 kg reaction crude was a biphasic system consisting of a toluene solution of the esters and an acid aqueous phase.
- 3055 kg of acidic waters were discharged from the bottom of the reactor for treatment and 61 .8 kg of 50% aqueous sodium hydroxide were added to basify the environment and to bring all the acid into the water as sodium salt.
- 1091 kg of toluene solution were obtained and 1724 kg of an aqueous phase which contained salified chrysanthemic acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention concerns the field of enzyme mutants, and in particular Arthrobacter globiformis esterase mutants suitable for asymmetrical hydrolysis of the cyclopropane derivatives, specifically chrysanthemate ester in any combination of the four stereoisomers in order to selectively obtain (1R,3R)-chrysanthemic acid or a salt thereof. The invention further describes an expression vector including the Arthrobacter globiformis esterase mutant and transformed host microorganisms harboring the vectors. The present invention further relates to the use of Arthrobacter globiformis esterase mutants to selectively obtain (1R,3R)-chrysanthemic acid. Under a further aspect, the invention relates to the use of Arthrobacter globiformis esterase mutants for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters, preferably for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
Description
NOVEL ESTERASE MUTANTS AND USES THEREOF AS STEREOSELECTIVE CATALYST
FIELD OF THE INVENTION
The present invention concerns the field of enzyme mutants, and in particular Arthrobacter globiformis esterase mutants suitable for asymmetrically hydrolyzing the cyclopropane derivatives, specifically chrysanthemate ester in any combination of the four stereoisomers in order to selectively obtain (1 R,3F?)-chrysanthemic acid or a salt thereof.
The invention further describes an expression vector including the Arthrobacter globiformis esterase mutant and transformed host microorganisms harboring the vectors.
The present invention further relates to the use of Arthrobacter globiformis esterase mutants to selectively obtain (1 R,3R)-chrysanthemic acid. Under a further aspect, the invention relates to the use of Arthrobacter globiformis esterase mutants for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters, preferably for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
STATE OF THE ART
Tanacetum cinerariifolium or Dalmatian chrysanthemum is a species of white flowering plant in the aster family, which was formerly part of the genus Pyrethrum, but now placed in the genus Chrysanthemum.
This plant is a natural source of "pyrethrum” insecticides, thereby giving it a great economic importance. The flowers are pulverized and the active components, called pyrethrins, contained in the seed cases, are extracted and sold in the form of an oleoresin which can be applied as a suspension in water or oil, or as a powder.
Pyrethrins are a mixture of six structurally related insecticidal esters formed by a combination of two acids (chrysanthemic acid and pyrethric acid) and different alcohols. The esters of chrysanthemic acid are called pyrethrin I, cinerin I, and jasmolin I, respectively, and are together known as pyrethrins I, whereas the esters of pyrethric acid are called pyrethrin II, cinerin II, and jasmolin II, and together, the pyrethrins II
Pyrethrins attack the nervous systems of all insects, inhibiting female mosquitoes from biting. When present in amounts less than those fatal to insects, they still appear to have an insect repellent effect.
They are harmful to fish but are far less toxic to mammals and birds than many synthetic insecticides and are not persistent, being biodegradable and also decompose easily on exposure to light. They are considered to be amongst the safest insecticides for use around food.
After the chemical structure of “natural pyrethrins” was elucidated, useful synthetic pyrethroids provided with various characteristics have been developed, leading to the advancement of pyrethroid chemistry.
The Chrysanthemic acid is the peculiar intermediate that is related to a variety of natural and synthetic insecticides. In particular, the pyrethroids are derivatives of the chrysanthemic acid that can be found in different possible 4 stereoisomers i.e. (1 R,3R) or (1 R,3S) or (1 S,3R) or (1 S,3S).
The (1 R,3R)- or (+)-trans-chrysanthemic acid (one of the four stereoisomers) is generally considered as the most interesting and effective of the four stereoisomers:
(1 R,3R)- or (+)-frans-chrysantemic acid
Specifically, as also reported in Nishizawa et al. (“Stereoselective Production of (+)- trans-Chrysanthemic Acid by a Microbial Esterase: Cloning, Nucleotide Sequence, and Overexpression of the Esterase Gene of Arthrobacter globiformis in Escherichia coli; Appl Environ Microbiol. 1995; 61 : 3208-15), a highly stereoselective enzymatic production of the (+)-trans-chrysanthemic acid would have a great advantage over the conventional chemical processes to selectively obtain the target isomer. The Esterase Gene of Arthrobacter globiformis was characterized and reported to be highly
stereospecific, although difficult to use in large scale production of insecticides, due to product inhibition.
It is therefore object of the present invention the development of a stereoselective hydrolysis of the chrysanthemic esters. It is known that the chrysanthemic acid can be obtained by hydrolysis of the appropriate chrysanthemic esters, in particular of ethyl chrysanthemate in racemic form.
The ethyl chrysanthemate (or related esters) can be found in four isomers:
(IS)-trans-ethyl chrysanthemate or (1S,3S)- ethyl chrysanthemate
(lR)-c/s-ethyl chrysanthemate or (1R,3S)- ethyl chrysanthemate
The stereoisomer mixture is the starting material for producing the chrysanthemic acid. A further object of the present invention is hence to selectively produce the (1 R,3R) chrysanthemic acid from the ethyl chrysanthemate racemate.
SUMMARY OF THE INVENTION
The inventors surprisingly found a new esterase capable of selectively hydrolyzing an ester racemate of chrysanthemic acid to selectively produce (1 R,3R) chrysanthemic acid or salts thereof.
The present invention hence concerns an Arthrobacter globiformis esterase mutant having a sequence comprising mutations of amino acid residue S at position 315, amino acid residue S at position 223 or amino acid residue F at position 298 of SEQ ID NO: 2.
Under a second aspect, the present invention regards an expression vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
A third aspect of the present invention relates to a transformed host microorganism containing the expression vector, said vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
In a fourth aspect, the present invention relates to the use of an Arthrobacter globiformis esterase mutant according to the invention, for the selective preparation of (1 F?,3F?)-chrysanthemic acid.
In a preferred aspect the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing cyclopropane racemate derivatives having at least two chiral stereocenters.
Therefore, in a fifth aspect the invention relates to the use of the Arthrobacter globiformis esterase mutant for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
In a preferred and advantageous aspect the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing (C-i-Ce) alkyl chrysanthemate, preferably ethyl chrysanthemate.
Therefore, in a sixth aspect the invention relates to the use of the Arthrobacter globiformis esterase mutant for asymmetrically hydrolyzing (C-i-Ce) alkyl chrysanthemate, preferably ethyl chrysanthemate.
As will be further described in the detailed description of the invention, the solution underlying the present invention is that of making available an innovative esterase with improved properties in obtaining the desired (1 R,3R) chrysanthemic acid for the production of pyrethroid insecticides.
The problem of providing (1 F?,3F?)-chrysanthemic acid is solved by the present finding, particularly by the identification of mutants of the Arthrobacter globiformis esterase, having an improved enzyme kinetic, an improved enzyme stability and/or a reduced product inhibition when compared to the wild-type Arthrobacter globiformis esterase of SEQ ID NO:2, as identified in the attached claims.
BRIEF DESCRIPTION OF THE DRAWINGS
The characteristics and advantages of the present invention will be apparent from the detailed description reported below, from the Examples given for illustrative and nonlimiting purposes, and from the annexed Figures 1 -10, wherein:
Figure 1 : Comparison of the specific activity of raw extracts of cells expressing different esterase enzyme variants.
The activity, expressed as a percentage of the specific activity of the wild-type enzyme, was measured using 10% (v/v) racemate of ethyl ester of chrysanthemic acid as a substrate, measuring (1 F?,3F?) chrysanthemic acid formation by HPLC analysis.
Figure 2. Schematic representation of the functioning of the gene library generation kit: 1 . Megaprimer mutants synthesis: amplification of the gene encoding for the esterase S315M using a DNA polymerase prone to insertion mutations allows to obtain the gene variants which are purified. 2. Vector Libraries containing mutated genes generated in 1. are used as a megaprimer to amplify the target vector using a high-fidelity DNA Polymerase to obtain a library of vectors containing mutated gene versions of the
S315M esterase enzyme. Figure 3: Representative graph of the variation of the specific activity as a function of the product concentration per an enzyme affected by product inhibition. Figure 4: Schematic representation of the selection scheme of the enzymatic variants obtained through random mutagenesis. Figure 5. Percentage increase in the residual activity of the 61 selected variants compared to the starting enzyme S315M. Figure 6. Percentage increase of the specific activity and hence of the inhibition in the presence of (1R,3R) chrysanthemic acid, of the 61 variants selected with respect to the starting enzyme S315M. Figure 7. Percentage increase in the residual activity of the 25 selected variants compared to the starting enzyme S315M. Figure 8. Chromatograms, obtained by HPLC analysis, relating to 20 hours of reaction conducted with the enzyme S315M and the mutated variants V274L-S315M-S331C (triple mutant), S315F, S223M. Figure 9. Calibration line of (1R,3R)-chrysanthemic acid: (1R,3R)-chrysanthemic acid amount (g/L) in pH stat and% yield of bioconversion for the enzymatic variants of the present invention and for the S315M enzyme used as a starting point for random mutagenesis. DETAILED DESCRIPTION OF THE INVENTION The present invention hence concerns an Arthrobacter globiformis esterase mutant having a sequence comprising mutations of amino acid residue S at position 315, amino acid residue S at position 223 or amino acid residue F at position 298 of SEQ ID NO: 2. Without being bound to any theory the inventors deem that the Arthrobacter globiformis esterase mutants herein claimed allow to obtain a higher yield in the selective conversion of cyclopropane derivatives having at least two chiral centers, preferably the racemate of (C1-C6) alkyl ester of chrysanthemic acid to (1R,3R)-chrysanthemic acid or a salt thereof, more preferably the racemate of ethyl ester of chrysanthemic acid:
A l bi i
by influencing the following three aspects of the catalysis: i) improved enzyme stability at different temperatures and pH values: the enzyme has good operational stability under basic conditions, in the pH range between 9.0 and 11.00. The best conversion yields are also obtained in this range, preferably in the 10.0-10.5 range, with significant decreases below 8.5-9.0; ii) improved kinetic parameters; and iii) reduction of product inhibition, when compared to the wild-type Arthrobacter globiformis esterase with amino acid sequence described in SEQ ID NO:2. The mutants described have undergone improved changes in catalytic performance, achieving conversion yields of up to 88-95% compared to what is achievable with WT enzyme with amino acid sequence reported in SEQ ID NO:2, which does not exceed values of 40-49%, with pH-stat during the reaction. The mutations have increased the affinity towards the substrate, without altering the high stereospecificity of the enzyme and decreasing the product inhibition that remains evident in WT enzyme. For the purposes of the present invention, the term: - “(1R,3R)-chrysanthemic acid” as used herein is intended to be synonymous to “(1R)- trans-chrysanthemic acid”, “(+)-trans-chrysanthemic acid” and “(1R,3R)- 2,2-Dimethyl- 3-(2-methyl-1-propenyl)cyclopropane-1-carboxylic acid” and having the CAS number 4638-92-0; - “(1R,3R)-chrysanthemic acid or its salts” means a salt of a metal selected from alkali metals and earth alkali metals such as potassium, sodium, calcium, magnesium, etc.; - “cyclopropane derivatives having at least two chiral centers” means cyclopropane compounds having at least two asymmetric carbon atoms so as to have at least two
stereoisomers, preferably four stereoisomers;
- “(C-i-Ce) alkyl esters of chrysanthemic acid” means esters of a linear or branched alkyl chain of 1 to 6 carbon atoms of chrysanthemic acid, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, hexyl, etc.;
- “Ethyl ester of chrysanthemic acid” as used herein is intended to be synonymous to “ethyl 2,2-dimethyl-3-(2-methylprop-1 -enyl)cyclopropane-1 -carboxylate” and has the CAS number 97-41 -6. According to the present invention, the ethyl ester of chrysanthemic acid can be provided in any ratio of trans/cis forms, for example from 60/40 to 100/0, preferably 65/35, 70/30, 80/20, 90/10, 92/8, 98/2.
In a preferred aspect, in the Arthrobacter globiformis esterase mutant according to the present invention said amino acid residue S at position 315, said amino acid residue S at position 223 and said amino acid residue F at position 298 of SEQ ID NO: 2 are replaced with a non-polar amino acid residue chosen from the group consisting of M, F, L, W, A, I, P or V. It was surprisingly seen by the inventors that by replacing the amino acid residues present in position 315, 223 or 298 of SEQ ID NO:2 with a nonpolar amino acid, the characteristics of the esterase enzyme are improved and maintains the capability of asymmetrically hydrolyzing racemic esters of chrysanthemic acid.
For the purposes of the present invention, amino acid residues are indicated by their “one letter code”, wherein “M” corresponds to Met or methionine, “F” corresponds to Phe or phenylalanine, “S” corresponds to Ser or serine and so on, as a person with ordinary skill in the art would understand.
In a more preferred aspect, in the Arthrobacter globiformis esterase mutant of the present invention, said amino acid residue S at position 315, said amino acid residue S at position 223 and said amino acid residue F at position 298 of SEQ ID NO: 2 are replaced with a non-polar amino acid residue chosen from the group consisting of M, F, L or W.
In a still more preferred aspect, the Arthrobacter globiformis esterase mutant of the present invention, has one of the following mutations S315M, S315F, S223M, S223L, S223F or F298W in the amino acid sequence of SEQ ID NO: 2.
In a still more preferred aspect, the Arthrobacter globiformis esterase mutant of the present invention, has one further mutation (double mutant) or two further mutations (triple mutant), and is preferably chosen from the group consisting of:
- the double mutant having the mutations S315M and S223M in the amino acid sequence of SEQ ID NO: 2;
- the double mutant having the mutations S315F and S223M in the amino acid sequence of SEQ ID NO: 2; and
- the triple mutant having the mutations S315M, V274L and S331 C in the amino acid sequence of SEQ ID NO: 2.
Preferred Arthrobacter globiformis esterase mutants have the following amino acid sequences: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20.
More preferably the Arthrobacter globiformis esterase mutant according to the present invention has the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 10 or SEQ ID NO: 12.
Still more preferably the Arthrobacter globiformis esterase mutant according to the present invention has the amino acid sequence of SEQ ID NO: 12 and a corresponding nucleotide sequence such as SEQ ID NO:11 . This mutant is the S315M mutant of the Arthrobacter globiformis esterase.
The invention also provides for the nucleotide sequences of the Arthrobacter globiformis esterase mutants, the mutants have the nucleotide sequences described in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
Under a second aspect, the present invention regards an expression vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
A third aspect of the present invention relates to a transformed host microorganism containing the expression vector, said vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO:
3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
In a fourth aspect, the present invention relates to the use of an Arthrobacter globiformis esterase mutant according to the invention, for the selective preparation of (1 F?,3F?)-chrysanthemic acid or a salt thereof.
In a preferred aspect the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing cyclopropane racemate derivatives having at least two chiral stereocenters.
Therefore, in a fifth aspect the invention relates to the use of the Arthrobacter globiformis esterase mutant for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
In a preferred and advantageous aspect, the invention relates to the Arthrobacter globiformis esterase mutant being capable of asymmetrically hydrolyzing (C-i-Ce) alkyl esters of chrysanthemic acid, preferably ethyl ester of chrysanthemic acid.
Therefore, in a sixth aspect the invention relates to the use of the Arthrobacter globiformis esterase mutant for asymmetrically hydrolyzing (C-i-Ce) alkyl ester of chrysanthemic acid, preferably ethyl ester of chrysanthemic acid.
For the purposes of the present disclosure, each Arthrobacter globiformis esterase sequence (wild type and mutant) has a corresponding SEQ ID NO: as follows, wherein for each mutant sequence the mutated nucleotide triplet or amino acid is indicated in bold and underlined:
SEQ ID NO:1 corresponds to the nucleotide sequence of:
Carboxylic ester hydrolase Arthrobacter globiformis esterase Q44050 (Wild type) ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACAGCGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAGCCCGTACGG
TAGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGG
ATCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGT
GGCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTA
CCGAACTGGCGCAATGA
SEQ ID N0:2 corresponds to the amino acid sequence of:
Carboxylic ester hydrolase Arthrobacter alobiformis esterase Q44050 (Wild type)
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANSAVGD
ILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETIQ
TVTAEQVFGIDRVFGETSCFGTVFMKSHARSPYGSYRAFGHDGASASLGFADPVYE
LAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID NO:3 corresponds to the nucleotide sequence of:
Arthrobacter alobiformis esterase mutant S223M (variant 9)
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACAIGGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAGCCCGTACGG
TAGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGG
ATCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGT
GGCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTA
CCGAACTGGCGCAATGA
SEQ ID N0:4 corresponds to the amino acid sequence of:
Arthrobacter alobiformis esterase mutant S223M (variant 9)
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANMAVG
DILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETI
QTVTAEQVFGIDRVFGETSCFGTVFMKSHARSPYGSYRAFGHDGASASLGFADPV
YELAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID NO:5 corresponds to the nucleotide sequence of:
Arthrobacter alobiformis esterase mutant S223L (variant 15)
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACTIGGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAGCCCGTACGG
TAGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGG
ATCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGT
GGCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTA
CCGAACTGGCGCAATGA
SEQ ID N0:6 corresponds to the amino acid sequence of:
Arthrobacter alobiformis esterase mutant S223L (variant 15)
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANLAVGD
ILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETIQ
TVTAEQVFGIDRVFGETSCFGTVFMKSHARSPYGSYRAFGHDGASASLGFADPVYE
LAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID N0:7 corresponds to the nucleotide sequence of:
Arthrobacter globiformis esterase mutant S223F (variant 16)
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACIUGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAGCCCGTACGG
TAGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGG
ATCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGT
GGCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTA
CCGAACTGGCGCAATGA
SEQ ID NO:8 corresponds to the amino acid sequence of:
Arthrobacter globiformis esterase mutant S223F (variant 16)
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANFAVGD
ILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETIQ
TVTAEQVFGIDRVFGETSCFGTVFMKSHARSPYGSYRAFGHDGASASLGFADPVYE
LAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID N0:9 corresponds to the nucleotide sequence of:
Arthrobacter alobiformis esterase mutant S315F (variant 18)
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACAGCGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTTUCCGTACGGT
AGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGGA
TCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGTG
GCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTAC
CGAACTGGCGCAATGA
SEQ ID NO:10 corresponds to the amino acid sequence of:
Arthrobacter globiformis esterase mutant S315F (variant 18)
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANSAVGD
ILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETIQ
TVTAEQVFGIDRVFGETSCFGTVFMKSHARFPYGSYRAFGHDGASASLGFADPVYE
LAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID N0:11 corresponds to the nucleotide sequence of:
Arthrgbacter glgbifgrmis esterase mutant S315M (variant 19)
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACAGCGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAIGCCGTACGGT
AGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGGA
TCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGTG
GCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTAC
CGAACTGGCGCAATGA
SEQ ID N0:12 corresponds to the amino acid sequence of:
Arthrobacter globiformis esterase mutant S315M (variant 19)
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANSAVGD
ILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETIQ
TVTAEQVFGIDRVFGETSCFGTVFMKSHARMPYGSYRAFGHDGASASLGFADPVY
ELAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID NO:13 corresponds to the nucleotide sequence of:
Arthrobacter globiformis esterase mutant F298W (variant 20)
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACAGCGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTGGGGTGA
AACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAGCCCGTACG
GTAGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCG
GATCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGG
GTGGCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGT
TACCGAACTGGCGCAATGA
SEQ ID N0:14 corresponds to the amino acid sequence of:
Arthrobacter globiformis esterase mutant F298W (variant 20)
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANSAVGD
ILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETIQ
TVTAEQVFGIDRVWGETSCFGTVFMKSHARSPYGSYRAFGHDGASASLGFADPVY
ELAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID NO:15 corresponds to the nucleotide sequence of:
Arthrobacter globiformis esterase double mutant S315M + S223M
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACAIGGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAIGCCGTACGGT
AGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGGA
TCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGTG
GCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTAC
CGAACTGGCGCAATGA
SEQ ID N0:16 corresponds to the amino acid sequence of:
Arthrobacter globiformis esterase double mutant S315M + S223M
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANMAVG
DILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETI
QTVTAEQVFGIDRVFGETSCFGTVFMKSHARMPYGSYRAFGHDGASASLGFADPV
YELAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID NO:17 corresponds to the nucleotide sequence of:
Arthrobacter globiformis esterase double mutant S315F + S223M
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC
CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA
CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT
CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC
GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC
CGGCGAGCCACTTTGGTCTGAGCGCGAACAIGGCGGTGGGTGACATTCTGGAT
CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG
TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGGTGGCGCCGCTGCTGAGCGAGGAAACC
ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA
ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTTUCCGTACGGT
AGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGAGCCTGGGTTTCGCGGA
TCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGTG
GCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTAC
CGAACTGGCGCAATGA
SEQ ID N0:18 corresponds to the amino acid sequence of:
Arthrobacter alobiformis esterase double mutant S315F + S223M
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG
VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG
VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ
EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANMAVG
DILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAAVAPLLSEETI
QTVTAEQVFGIDRVFGETSCFGTVFMKSHARFPYGSYRAFGHDGASASLGFADPVY
ELAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
SEQ ID NO:19 corresponds to the nucleotide sequence of:
Arthrobacter alobiformis esterase triple mutant S315M + V274L + S331 C
ATGGACGCGCAGACCATTGCGCCGGGTTTTGAGAGCGTGGCGGAACTGTTCGG
CCGTTTTCTGAGCGAGGATCGTGAATACAGCGCGCAACTGGCGGCGTATCACC
GTGGTGTGAAGGTTCTGGACATCAGCGGTGGCCCGCACCGTCGTCCGGATAGC
GTGACCGGCGTTTTTAGCTGCAGCAAAGGTGTGAGCGGCCTGGTTATTGCGCT
GCTGGTTCAGGACGGTTTCCTGGACCTGGATGCGGAAGTGGTTAAGTACTGGC
CGGAGTTTGGTGCGGAAGGCAAAGCGACCATTACCGTGGCGCAGCTGCTGAGC
CACCAAGCGGGTCTGCTGGGCGTTGAAGGTGGCCTGACCCTGGCGGAGTACAA
CAACAGCGAACTGGCTGCGGCGAAGCTGGCGCAAATGCGTCCGCTGTGGAAAC CGGGTACCGCGTTCGGCTATCACGCGCTGACCATCGGTGTGTTTATGGAGGAA CTGTGCCGTCGTATTACCGGCAGCACCCTGCAGGAGATCTACGAACAACGTATT CGTAGCGTTACCGGTGCGCACTTCTTTCTGGGTCTGCCGGAGAGCGAGGAACC GCGTTATGCGACCCTGCGTTGGGCGGCGGACCCGAGCCAGCCGTGGATTGATC CGGCGAGCCACTTTGGTCTGAGCGCGAACAGCGCGGTGGGTGACATTCTGGAT CTGCCGAACCTGCGTGAGGTTCGTGCGGCGGGTCTGAGCAGCGCGGCGGGCG TGGCGAGCGCGGAGGGTATGGCGCGTGTTTATGCTGCGGCGCTGACCGGTCT
GGCGGCGAACGGTGACCGTGCGGCGCTIGCGCCGCTGCTGAGCGAGGAAACC ATCCAGACCGTGACCGCGGAGCAAGTTTTCGGCATTGATCGTGTGTTTGGTGAA ACCAGCTGCTTCGGCACCGTTTTTATGAAGAGCCACGCGCGTAIGCCGTACGGT AGCTATCGTGCGTTCGGTCATGATGGTGCGAGCGCGTGTCTGGGTTTCGCGGA TCCGGTGTACGAGCTGGCGTTTGGCTATGTGCCGCAGCAAGCGGAGCCGGGTG GCGCGGGTTGCCGTAACCTGGAACTGAGCGCGGCGGTGCGTAAAGCGGTTAC CGAACTGGCGCAATGA
SEQ ID NO:20 corresponds to the amino acid sequence of:
Arthrobacter globiformis esterase triple mutant S315M + V274L + S331 C
MDAQTIAPGFESVAELFGRFLSEDREYSAQLAAYHRGVKVLDISGGPHRRPDSVTG VFSCSKGVSGLVIALLVQDGFLDLDAEVVKYWPEFGAEGKATITVAQLLSHQAGLLG VEGGLTLAEYNNSELAAAKLAQMRPLWKPGTAFGYHALTIGVFMEELCRRITGSTLQ EIYEQRIRSVTGAHFFLGLPESEEPRYATLRWAADPSQPWIDPASHFGLSANSAVGD ILDLPNLREVRAAGLSSAAGVASAEGMARVYAAALTGLAANGDRAALAPLLSEETIQ TVTAEQVFGIDRVFGETSCFGTVFMKSHARMPYGSYRAFGHDGASACLGFADPVY ELAFGYVPQQAEPGGAGCRNLELSAAVRKAVTELAQ
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention.
Example 1. Generation of a gene library of mutants encoding for the esterase enzyme
1045 variants of the esterase enzyme were generated by random mutagenesis, in order to select enzyme variants with a decreased product inhibition by High Throughput Screening (HTS).
Specifically, the most promising mutant, the S315M mutant (also referred to as variant 19) was obtained.
In particular the S315M esterase mutant is characterized by a higher activity on the ester of chrysanthemic acid substrate and is used as a starting point (template) for a random mutagenesis cycle, as here described.
The gene library was generated by random mutagenesis performed by using the commercial kit Genemorph II Random Mutagenesis Kit (Agilent cat. N° 200550), using the S315M esterase gene as a template (Figure 2).
As described in Figure 2, the method is divided into 2 phases:
1. The gene encoding the S315M esterase enzyme is used as a template in a PCR reaction conducted using the error-prone Mutazyme II DNA polymerase, and an amount of DNA and amplification cycles such as to determine a low mutation frequency, i.e. 0-4.5 mutations I Kbase. The gene variants thus obtained were loaded onto gel and the corresponding band was excised and then purified.
2. The gene variants of the S315M enzyme, generated in phase 1 , were used as megaprimer for the amplification of the target vector (generically a vector with a T7 promoter) by means of a high-fidelity DNA polymerase to avoid the introduction of mutations in the backbone of the vector. The mutated vector library was then purified and subsequently used for the transformation of E. coli cells.
Example 2. Gene library expression in overproducing E. coli cells
The “Esterase mutant” vector library was first fully amplified in E. coli DH5a. Following the amplification, plasmid DNA extraction was carried out as well as the transformation of overexpressing E. coli cells, suitable for gene expression.
The cells thus transformed were plated on selective medium obtaining 10,832 colonies, after incubation over-night at 37°C.
Of these, 1045 were randomly selected to then proceeded to the gene expression and subsequently to HTS.
Each colony was inoculated into a deep well in 1 mL of ZYM5052 medium containing lactose, which is able to induce the expression of the genes encoding the variants of the esterase enzyme, inserted in the vector.
After an incubation of 24 hours at 37 °C the cells were collected by centrifugation and the pellet was processed for subsequent analyses.
Example 3. High Throughput Screening (HTS) for the selection of enzymatic variants with decreased product inhibition
In enzymatic reactions the enzymes may be subject to inhibition by the substrate or by the product.
Substrate inhibition: In this case, there is a decrease in the initial specific activity as a function of substrate concentration.
Product inhibition: In this case, the specific activity decreases until it becomes zero only when a certain concentration of product is accumulated, Figure 3 is representative of the phenomenon. As a direct consequence, an incomplete bioconversion of the substrate into the product could occur.
Specifically, as reported in Nishizawa et al. (“Stereoselective Production of (+)-trans- Chrysanthemic Acid by a Microbial Esterase: Cloning, Nucleotide Sequence, and Overexpression of the Esterase Gene of Arthrobacter globiformis in Escherichia coli; Appl Environ Microbiol. 1995; 61 : 3208-15), the esterase enzyme object of the present study is subject to product inhibition, therefore in the mutant screening the specific activity was evaluated both in the absence and in the presence of the product, ( 1R,3R)- chrysanthemic acid, providing the chromogenic substrate p-nitro-phenyl-butyrate. The concentration of (1 R,3R) chrysanthemic acid tested is equal to 100 mM, value chosen as obtained at the end of the bioconversion conducted with the S315M enzyme.
The inhibition was then evaluated in terms of percentage of residual activity, or the percentage ratio between the specific activity with acid and the specific activity without acid. Consequently, the higher the percentage of residual activity, the lower the degree of inhibition.
Experimental protocol:
Previously collected cell pellets were lysed by resuspension in 200 pL of Cellytic™ (enzymatic cocktail in detergent) and incubation at room temperature for 2 hours in agitation. The obtained lysate was clarified by centrifugation and the supernatant, ie. the total crude extract was used, after dilution, for screening.
Screening was set up in 96-well multiplate and reactions were conducted at a temperature of 25°C for 10 minutes in 100 mM sodium phosphate buffer providing the substrate chromogenic p-nitro-phenyl-butyrate at the final concentration of 4 mM, in the absence and presence of (1 R,3R) chrysanthemic acid at the final concentration of 100 mM. The absorbance was monitored over time by acquiring readings at 405 nm every 16 seconds.
The enzymatic activity (U/mL) is therefore defined as:
where E is the molar extinction coefficient of para-nitro-phenol.
In order to calculate the specific activity (U/mg) of the enzymatic variants in the presence or absence of the acid, the total proteins in the crude extracts were quantified through the Bradford method, using BSA as the reference protein for the calibration curve.
The HTS procedure allowed to obtain and select 25 enzyme variants.
Example 4. Quantification of (1 R, 3R) chrysanthemic acid by HPLC in 25 selected enzymatic variants
The production of (1 R,3R) chrysanthemic acid was evaluated for the 25 enzymatic variants selected by HTS to which chrysanthemic acid ethyl ester was added as a substrate. Specifically, the acid product was quantified by reverse-phase HPLC analysis, with a gradient elution of a solution composed of 50% Methanol 50% Acetonitrile and 0.1 % TFA.
The quantification of (1 R,3R) chrysanthemic acid allowed for: i) the calculation of the specific enzymatic activity (U/mg) on chrysanthemic acid ethyl
ester defined as
A [(!/?, 37?) chrysanthemic acid] min * [proteins in the raw extract] ii) the calculation of the % yield of bioconversion of the chrysanthemic ethyl ester substrate in (1 R,3R) chrysanthemic acid in experiments conducted at constant pH (pH stat).
This value is calculated by making the ratio between the acid produced (g/L) and the maximum amount of acid obtainable (g/L).
Figure 4 summarizes the selection scheme carried out and discussed below.
Following the HTS conducted on 1045 samples providing the chromogenic substrate p-nitro-phenylbutyrate, it was found that 61 variants of the starting enzyme S315M show characteristics improved in terms of:
• increased residual activity%, or decreased inhibition from the product
• increased specific activity (ll/rng) in the presence of (1 R,3R) - chrysanthemic acid.
In particular, as regards the residual activity %, all 61 selected enzymes have an increase in residual activity compared to the starting enzyme of at least 25%.
Figures 5 and 6 show the % increase in residual and specific activity (in the presence of (1 F?,3F?)-chrysanthemic acid) of each mutant with respect to the starting enzyme S315M.
Of these 61 enzymatic variants we have selected 25 which have been retested by “scaling up” the procedure.
Specifically, the growth of the 25 E. coli clones expressing the 25 enzymatic variants was performed in 250 mL flasks with 25 mL of self-inducing medium, instead of 1 mL deep wells.
The specific activity in the presence and absence of acid was therefore re-evaluated by providing the substrate chromogenic p-nitro-phenyl-butyrate and the % increase in residual activity was calculated with respect to the starting enzyme S315M (Figure 7). All 25 enzyme variants (resulting from flask-scale bacterial growth) exhibit a % increase
in residual activity compared to the S315M enzyme, confirming what has been observed in the HTS, albeit with some variation in the absolute values.
The 25 variants were also tested by providing the ethyl ester of chrysanthemic acid substrate.
Bioconversion of the 3 selected enzymatic variants (V274L-S315M-S331 C - S315F - S223M) in pH stat
The selection of the three comparison mutants with the S315M reference was made from the previous 25 mutants by performing small-scale bioconversions with the chromogenic substrate but in the presence of chrysanthemic acid in the reaction mixture. The mutants with greater activity in the presence of the potential inhibitor (product inhibition) were then selected, thus demonstrating less influence from the acid. Subsequently, performance is naturally estimated with the substrate of interest. Specifically, the reaction in pH stat is carried out in a final volume of 20 mL in the presence of the racemate ethyl ester of chrysanthemic acid as substrate at 10% (v I v). The reaction is carried out at 45°C for 20 hours during which the pH is maintained at a value of 9.5 by the addition of 1 M NaOH. At the end of the reaction, the amount of (1 R, 3R) -chrysanthemic acid is evaluated by HPLC analysis.
RESULTS AND CONCLUSIONS
Figure 8 shows the HPLC chromatograms of the previous bioconversion obtained after 20 hours of reaction (T20) using 10% chrysanthemic acid ethyl ester (v/v). Specifically, the peaks at about 2 min will refer to (1 R,3R) chrysanthemic acid while those at about 4.7 min are related to all the chrysanthemic acid ethyl esters, not converted.
In order to quantify the (1 R,3R) chrysanthemic acid produced at the end of the reaction, a calibration line (Figure 9), with a standard of the aforementioned acid, which correlates the peak area with the known acid concentration, expressed in g/L (Table 1 ) has been performed.
To determine the bioconversion yields, the maximum yield which is theoretically obtainable was first calculated. From the analysis of the starting mixture of isomers of ethyl ester of chrysanthemic acid, the enantiomer ethyl ester of (1 R,3R) chrysanthemic
acid is present at a concentration of 404.6 g/L. This mixture was used at 10% (v/v) therefore the reaction solution contained 40.46 g/L of ethyl ester of (1 R,3R)- chrysanthemic acid.
Considering the molecular weight of the resulting (1 F?,3F?)-chrysanthemic acid, the maximum acid concentration obtainable starting from 40.46 g / L of ester is equal to 34.67 g/L. Table 1 shows the data of (1 F?,3F?)-chrysanthemic acid (g/L) obtained and the relative yield % of bioconversion (% referred to the maximum theoretical obtainable yield). In addition, as a control, the previously obtained WT enzyme values are reported.
As reported above, the introduction of the point mutation S315M allowed to obtain a better catalyst than the wild-type enzyme, both in terms of specific activity (Figure 1 - mutant 19), and of a lower inhibition by product: the yield of bioconversion of (1 R, 3R)- chrysanthemic ethyl ester has in fact increased from 49.5% to 94.1 % (Table 1 ).
Furthermore, as shown in Table 1 , the performance of the S223M variant was similar to S315M enzyme; in fact, it transformed a high percentage of substrate after an incubation of 20 hours, with a yield of about 89%, compared to the theoretical maximum obtainable yield.
In conclusion, among the tested mutants, the S315M, S223M, S315F variants have proven to be the optimal ones to catalyze bioconversion of (1 F?,3F?)-ethyl ester of chrysanthemic acid to (1 R,3R)- chrysanthemic acid selectively from a mixture of the four possible stereoisomers.
Example 5. Enzymatic hydrolysis of racemate ethyl ester of chrysanthemic acid 92/8
Ethyl chrysanthemate 92/8 consisting of four stereoisomers was provided to produce (1 R,3R)- chrysanthemic acid by enzymatic hydrolysis reaction with the S315M mutant. The enzymatic hydrolysis reaction was conducted in batch; in addition to the 92/8 trans I cis ester mixture, glycine, enzyme and aqueous sodium hydroxide were loaded in a reactor, the function of which was to maintain the alkaline environment for the entire duration of the reaction. At the end of the reaction, the enzyme, degraded in an acidic environment by hydrochloric acid and denatured with trichloroacetic acid, was removed by filtration. The remaining solution containing the unconverted esters and the desired (1 R,3R) chrysanthemic acid was added with toluene to dissolve the esters and added with a solution (10% w/w) of aqueous sodium hydroxide to bring the chrysanthemic acid into water in the form of sodium salt. From the separation of these two phases, a toluene solution was obtained containing the unconverted esters which were fed to the subsequent workup stage; from the aqueous phase after acidification the product ( 1R,3R) chrysanthemic acid was recovered by extraction with toluene and subsequent evaporation of the solvent.
The reaction was carried out on 400 kg of racemate ethyl ester of chrysanthemic acid 92/8 with 16.7 kg of glycine, 444 kg of enzyme dissolved in water, 413 kg of 10% aqueous sodium hydroxide in 3556 kg of water. At the end of the reaction, the raw material was acidified with 1 16 kg of 37% hydrochloric acid and treated with 11 .6 kg of trichloroacetic acid to denature the enzyme and allow it to be filtered. From filtration approximately 17.4 kg of denatured enzyme were obtained and sent for disposal and a solution of toluene and water was introduced for washing the filter and extracting the esters using about 868 kg of it.
The 5808 kg reaction crude was a biphasic system consisting of a toluene solution of the esters and an acid aqueous phase. 3055 kg of acidic waters were discharged from the bottom of the reactor for treatment and 61 .8 kg of 50% aqueous sodium hydroxide were added to basify the environment and to bring all the acid into the water as sodium salt.
From the separation of the phases, 1091 kg of toluene solution were obtained and 1724 kg of an aqueous phase which contained salified chrysanthemic acid. 77 kg of 37% (w/w) hydrochloric acid were added to this aqueous phase to result in the desired (1 R,3R) chrysanthemic acid and 253 kg of toluene to bring it into the organic phase. After the separation of 1666 kg of water to be sent for disposal, the toluene of the organic phase was evaporated, finally separating 135 kg of ( 1R,3R) chrysanthemic acid, as unique (1 R,3R) form, and with a purity greater than 95%.
From the above description and the above-noted examples, the advantage attained by the product described and obtained according to the present invention are apparent.
Claims
1. An Arthrobacter globiformis esterase mutant having a sequence comprising mutations of amino acid residue S at position 315, amino acid residue S at position 223 or amino acid residue F at position 298 of SEQ ID NO: 2.
2. The Arthrobacter globiformis esterase mutant according to claim 1 , wherein said mutant is capable of asymmetrically hydrolyzing racemic esters of chrysanthemic acid.
3. The Arthrobacter globiformis esterase mutant according to any one of claims 1 or 2, wherein said amino acid residue S at position 315, said amino acid residue S at position 223 and said amino acid residue F at position 298 of SEQ ID NO: 2 are replaced with a non-polar amino acid residue chosen from the group consisting of M, F, L, W, A, I, P or V.
4. The Arthrobacter globiformis esterase mutant according to claim 3, wherein said non-polar amino acid residue is chosen from the group consisting of M, F, L or W.
5. The Arthrobacter globiformis esterase mutant according to any one of claims 1 to 4, having one of the following mutations S315M, S315F, S223M, S223L, S223F or F298W in the amino acid sequence of SEQ ID NO: 2.
6. The Arthrobacter globiformis esterase mutant according to claim 5, having one or two further mutations chosen from the group consisting of:
- the double mutant having the mutations S315M and S223M in the amino acid sequence of SEQ ID NO: 2;
- the double mutant having the mutations S315F and S223M in the amino acid sequence of SEQ ID NO: 2; and
- the triple mutant having the mutations S315M, V274L and S331 C in the amino acid sequence of SEQ ID NO: 2.
7. The Arthrobacter globiformis esterase mutant according to any one of claims 1 to 6, wherein said mutant has the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20.
8. The Arthrobacter globiformis esterase mutant according to any one of claims 1 to 7, wherein said mutant has the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 10 or SEQ ID NO: 12.
9. The Arthrobacter globiformis esterase mutant according to anyone of claims 1 to 8, wherein said mutant has the amino acid sequence of SEQ ID NO: 12.
10. The Arthrobacter globiformis esterase mutant according to anyone of claims 1 to 9, wherein said mutant has the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO:19.
1 1. An expression vector including an Arthrobacter globiformis esterase mutant nucleotide sequence chosen from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 1 1 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO:19.
12. A transformed host microorganism containing the expression vector according to claim 1 1 , comprising the Arthrobacter globiformis esterase mutant nucleotide sequence.
13. Use of an Arthrobacter globiformis esterase mutant according to anyone of claims 1 to 10, for the selective preparation of (1 F?,3F?)-chrysanthemic acid or a salt thereof.
14. Use of an Arthrobacter globiformis esterase mutant according to anyone of claims
1 to 10, for the asymmetrical hydrolysis of cyclopropane racemate derivatives having at least two chiral stereocenters.
15. Use of an Arthrobacter globiformis esterase mutant according to anyone of claims 1 to 10, for asymmetrical hydrolysis of (C-i-Ce) alkyl ester of chrysanthemic acid, preferably ethyl ester of chrysanthemic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/070973 WO2024022580A1 (en) | 2022-07-26 | 2022-07-26 | Novel esterase mutants and uses thereof as stereoselective catalyst |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/070973 WO2024022580A1 (en) | 2022-07-26 | 2022-07-26 | Novel esterase mutants and uses thereof as stereoselective catalyst |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024022580A1 true WO2024022580A1 (en) | 2024-02-01 |
Family
ID=83081425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/070973 WO2024022580A1 (en) | 2022-07-26 | 2022-07-26 | Novel esterase mutants and uses thereof as stereoselective catalyst |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024022580A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0497103A2 (en) * | 1991-01-10 | 1992-08-05 | Sumitomo Chemical Company Limited | Gene encoding asymmetrically active esterase |
WO2020116331A1 (en) * | 2018-12-06 | 2020-06-11 | 天野エンザイム株式会社 | Modified chrysanthemic acid esterase |
-
2022
- 2022-07-26 WO PCT/EP2022/070973 patent/WO2024022580A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0497103A2 (en) * | 1991-01-10 | 1992-08-05 | Sumitomo Chemical Company Limited | Gene encoding asymmetrically active esterase |
WO2020116331A1 (en) * | 2018-12-06 | 2020-06-11 | 天野エンザイム株式会社 | Modified chrysanthemic acid esterase |
Non-Patent Citations (6)
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4359349B2 (en) | Production method of vanillin | |
WO2018217168A1 (en) | Bioproduction of phenethyl alcohol, aldehyde, acid, amine, and related compounds | |
DE102006025821A1 (en) | An enzyme for the production of Mehylmalonatsemialdehyd or Malonatsemialdehyd | |
DE102007015583A1 (en) | An enzyme for the production of methylmalonyl-coenzyme A or ethylmalonyl-coenzyme A and its use | |
RU2720094C2 (en) | Method for recovery and purification of ambroxide | |
Aleu et al. | Biocatalysis applied to the synthesis of agrochemicals | |
KR20130107355A (en) | Phenylpyruvate reductase and method for manufacturing optically-active phenyllactic acid and 4-hydroxyl-phenyllactic acid using same enzyme | |
JP6838968B2 (en) | Method for producing ester of 3-hydroxypropionic acid | |
JP2793812B2 (en) | Method for producing ibuprofen | |
US6472190B1 (en) | Biocatalytic synthesis of galloid organics | |
CH661498A5 (en) | OPTICALLY ACTIVE CHEMICAL INTERMEDIATES USEFUL FOR THE PRODUCTION OF L-CARNITINE AND PROCEDURES FOR THEIR PREPARATION. | |
CA2582969A1 (en) | Process for producing 4-vinylguaiacol by biodecarboxylation of ferulic acid | |
Yildirim et al. | Recombinant chlorobenzene dioxygenase from Pseudomonas sp. P51: a biocatalyst for regioselective oxidation of aromatic nitriles | |
WO2024022580A1 (en) | Novel esterase mutants and uses thereof as stereoselective catalyst | |
CN111197054A (en) | Construction of recombinant pseudomonas putida and application thereof in production of propionic acid | |
CN112176007A (en) | Preparation method of amino alcohol chiral intermediate | |
JPH01104195A (en) | Method for producing 2-aryloxy- propionic acid | |
JPH04234991A (en) | New microorganism | |
JP4501541B2 (en) | Process for producing optically active cyclopropanecarboxylic acid | |
NO319415B1 (en) | Microbial preparation of actinol | |
JP4857606B2 (en) | Process for producing optically active cyclopropanecarboxylic acid | |
JP2002253295A (en) | Method for producing (r)-1,2-propanediol by microbial culturing method | |
WO2024008622A1 (en) | Biopesticide composition | |
JP4793131B2 (en) | Process for producing optically active 2,3-dichloro-2-methyl-1-propanol and optically active 2-methylepichlorohydrin | |
JP2023160200A (en) | Method for producing biomass-derived muconic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22760658 Country of ref document: EP Kind code of ref document: A1 |